Imaging Catheters Market: as Terumo's dual-sensor OFDI-IVUS catheter and Abbott's AI-enhanced OCT platform both reach US clinical practice within the same year, combined-modality imaging is displacing the choice between IVUS and OCT entirely, so the competitive question is shifting from which single modality wins to which vendor delivers both without a second catheter insertion.

The global imaging catheters market size was USD 1.52 Billion in 2025 and is expected to register a revenue CAGR of 5.8% during the forecast period.Imaging catheters encompass IVUS, OCT, NIRS, and multimodality imaging catheters that provide real-time cross-sectional imaging of vessel wall architecture, plaque morphology, and stent apposition that guides interventional clinical decisions beyond conventional X-ray angiography.Market revenue growth is supported by the increasing clinical evidence base for intravascular imaging-guided PCI over angiography-only PCI, with the ACC and AHA's updated 2024 coronary revascularisation guidelines affirming intravascular imaging guidance as a Class IIa recommendation for complex lesion subsets.The Society for Cardiovascular Angiography and Interventions reported that IVUS-guided PCI utilisation rates exceeded 30% of all PCI procedures at high-volume academic interventional cardiology programmes.In November 2024, Boston Scientific launched AVVIGO, an AI-enabled multimodality guidance system combining IVUS and fractional flow reserve measurement, representing the first commercially launched combined IVUS-FFR system from a major device manufacturer.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a combined-modality imaging catheter widens its addressable revenue every time it captures a procedure that previously required two separate catheter insertions, converting a workflow inefficiency into a single-catheter commercial advantage.Once a hospital cath lab has a combined IVUS-OCT or IVUS-FFR system installed, every procedure that would have required choosing one modality and potentially re-inserting a second catheter for the complementary view instead captures both data streams in one pullback, so revenue per procedure compounds as combined-modality systems replace the single-modality installed base rather than requiring net new procedure volume.As a result, demand and revenue share are concentrating around vendors with genuine combined-modality catheter platforms, that eliminate the need to choose between IVUS's depth penetration and OCT's surface resolution, and the forecast tilts toward these dual-sensor systems rather than single-modality catheters.For instance, on June 15, 2026, Terumo completed the first US clinical procedure using its OPUSWAVE Dual Sensor Imaging System, which combines optical frequency domain imaging and intravascular ultrasound within a single DualView catheter, following FDA 510(k) clearance in October 2025 and marking the company's imaging debut in the US market.These are some of the key factors driving revenue growth of the market.

Because IVUS and OCT single-use catheters cost USD 400 to USD 800 and USD 500 to USD 900 respectively, this creates cost-benefit evaluation requirements at hospital catheterisation laboratory procurement committees that slow routine imaging catheter adoption in non-complex PCI procedures.

Third-party catheter reprocessing is a second constraint, as FDA-authorised reprocessing of catheters including Northeast Scientific's authorisation for the Philips Eagle Eye Platinum RX Digital IVUS catheter provides lower-cost alternatives that cannibalise new catheter sales at price-sensitive accounts.

Complex operator training requirements are a third constraint, as OCT interpretation and IVUS measurement skill requirements remain barriers to routine imaging adoption at lower-volume catheterisation laboratories outside academic and high-volume PCI programme settings.

These factors substantially limit imaging catheters market growth over the forecast period.

The clearest driver of demand is the rapid product cycle of combined imaging and physiology platforms from the category's largest vendors. A combined-modality imaging catheter only earns hospital adoption if it demonstrably reduces procedural steps without sacrificing image quality, and Boston Scientific's AVVIGO does exactly that by integrating IVUS morphological data with FFR functional significance data in a single intravascular interrogation. Boston Scientific launched its iCross Coronary Imaging Catheter in March 2024 with immediate US commercial availability, received CE mark for next-generation iLab System Software in September 2024, and launched AVVIGO in November 2024. On October 24, 2025, Terumo received FDA 510(k) clearance for its OPUSWAVE Dual Sensor Imaging System featuring the DualView catheter, which combines optical frequency domain imaging and intravascular ultrasound, and completed its first US clinical procedure on June 15, 2026 at Mount Sinai Fuster Heart Hospital. The effect on the market is that combined-modality imaging is now available from multiple major vendors in the US market, intensifying competition beyond single-modality IVUS or OCT product differentiation. These are some of the key factors driving revenue growth of the market.

The second driver is venture and corporate capital flowing into AI-enhanced imaging catheter differentiation beyond hardware alone. An AI-enhanced imaging catheter only justifies its premium if the software layer measurably reduces manual interpretation burden, and SpectraWAVE's HyperVue platform, backed by Johnson & Johnson Innovation's lead investment, is specifically designed to provide real-time automated plaque characterisation that goes beyond manual grayscale IVUS interpretation. Conavi Medical broadened the commercial reach of its Novasight hybrid IVUS-OCT imaging system in January 2025 through a Minnetronix partnership, with the PANOVISION clinical trial underway to generate evidence for the hybrid catheter's clinical utility. In May 2026, Abbott received FDA clearance and CE mark for its updated Ultreon 3.0 OCT platform, featuring a one-second OCT pullback technique that delivers higher-resolution readings than IVUS with low or zero contrast, plus enhanced AI-automated insights. The effect on the market is that AI-enabled plaque analysis and combined-modality imaging are becoming standard competitive expectations rather than premium differentiators, raising the baseline software sophistication required to compete. These are some of the key factors driving revenue growth of the market.

“Abbott's Ultreon 3.0 platform delivers a one-second OCT pullback with higher-resolution readings than IVUS at low or zero contrast, directly addressing the contrast-related kidney injury risk that has constrained OCT adoption in patients with renal impairment.”

However, the imaging catheters market faces severe adoption constraints from high per-procedure catheter cost, third-party catheter reprocessing competition, and complex operator training requirements.

Because IVUS and OCT single-use catheters cost USD 400 to USD 900 depending on modality, hospital catheterisation laboratory procurement committees require cost-benefit justification that slows routine adoption in non-complex PCI procedures.

Third-party catheter reprocessing is a second constraint, with FDA-authorised reprocessing of catheters including the Philips Eagle Eye Platinum RX Digital IVUS catheter providing lower-cost alternatives that cannibalise new catheter sales.

Complex operator training requirements are a third constraint, limiting routine imaging adoption outside high-volume academic PCI programmes where dedicated OCT interpretation and IVUS measurement expertise is concentrated.

These factors substantially limit imaging catheters market growth over the forecast period.

Based on type, the global imaging catheters market is segmented into IVUS, OCT, NIRS, and multimodality imaging catheters. IVUS catheters account for the largest revenue share at approximately 58% of 2025 market revenue. Philips Healthcare's Visions PV.035 catheter, Boston Scientific's iCross and Eagle Eye Platinum series, and Terumo's AltaView coronary IVUS catheter represent the primary commercial coronary IVUS catheter products. The peripheral IVUS catheter sub-segment was valued at USD 187.99 Million in 2024, representing the peripheral vascular imaging catheter growth segment driven by increasing IVUS guidance adoption in PAD, carotid, and renal artery interventions.

OCT catheters are expected to register the fastest revenue growth rate among imaging catheter types over the forecast period, with the segment expected to grow at a CAGR exceeding 8%. OCT imaging catheters provide near-field high-resolution cross-sectional imaging that enables stent strut-level assessment of stent apposition, tissue prolapse, and edge dissection that IVUS cannot resolve at equivalent magnification. Coronary artery disease accounts for approximately 72% of imaging catheter application revenue, with structural heart imaging expected to register the fastest application CAGR as intracardiac echocardiography catheter guidance for TAVR, MitraClip, and LAA closure procedures expands.

Based on regional analysis, North America accounted for approximately 40% of global imaging catheters revenue in 2025, with the US market at approximately USD 580 Million. North America's dominance reflects Medicare-backed payment certainty for IVUS-guided PCI under Category I CPT codes, deep cardiac catheterisation laboratory penetration, and the commercial concentration of Boston Scientific, Philips Healthcare, and Abbott as primary vendors. The FDA's approval cadence for AI-enabled IVUS systems including AVVIGO and Terumo's OPUSWAVE creates ongoing innovation-driven replacement procurement at US cath labs seeking to upgrade from older-generation imaging systems.

The market in Asia Pacific is expected to register the fastest revenue growth rate in the global imaging catheters market over the forecast period.

Japan, China, South Korea, and Australia represent the four largest national imaging catheter markets, with the region holding approximately 27% of global imaging catheters revenue. Japan's extremely high IVUS utilisation rate in PCI procedures, with Japanese guidelines recommending IVUS guidance for virtually all PCI procedures, makes Japan one of the highest per-procedure imaging catheter consumption markets globally. China's MicroPort MicroImaging Outsight Disposable IVUS Catheter NMPA approval expands the domestic Chinese IVUS catheter competitive landscape with a lower-cost domestic procurement alternative.

The market in Europe is expected to register a steady revenue growth rate in the global imaging catheters market over the forecast period.

Germany, France, the United Kingdom, and Italy represent the four largest national imaging catheter markets. The CE mark for Boston Scientific's next-generation iLab System Software supports continued European commercial expansion, and Abbott's Ultreon 3.0 CE mark alongside its FDA clearance reflects simultaneous transatlantic regulatory pursuit for next-generation OCT platforms.

Latin America and Middle East and Africa markets are expected to register moderate revenue growth rates in the global imaging catheters market over the forecast period.

Brazil and Mexico represent the two largest national imaging catheter markets in Latin America, with growing complex PCI programme development at private and academic tertiary hospital networks. Saudi Arabia and the UAE represent the primary GCC markets, with cardiac catheterisation laboratory investment under Saudi Vision 2030 supporting growing institutional imaging catheter procurement.